NCT02659293进行中（未招募）3 期
Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
- 试验地点
- 3
- 主要终点
- Progression free survival rates in participants receiving drug combination
研究概览
简要总结
This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.
详细描述
Primary Objective:
- To compare progression free survival between Kyprolis (Carfilzomib), Revlimid (lenalidomide), Dexamethasone (KRd) arm and lenalidomide arm
Secondary Objectives
- To determine the rate of minimal residual negative disease (MRD) at 6 and 12 months after randomization
- To compare the efficacy (rate of partial response, very good partial response, complete response, and stringent complete response) of KRd vs. Lenalidomide alone after randomization
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who completed single autologous stem cell transplant after completion of at most 2 induction regimens (excluding dexamethasone alone) and are in at least stable disease in the first 100 days after stem cell transplantation.
- •Patients must be within 12 months of initiation of induction therapy and must have had not more than 2 prior induction regimens.
- •Bone marrow specimen will be required at study entry; available DNA sample will be used for calibration step for MRD evaluation by gene sequencing.
- •Males and females ≥ 18 years of age
- •ECOG performance status of 0-1
- •Adequate hepatic function, with bilirubin ≤ 1.5 x ULN and aspirate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN
- •ANC ≥ 1.0 x 109/L, hemoglobin ≥ 8 g/dL, platelet count ≥ 75 x 109/L.
- •Calculated creatinine clearance (by Cockcroft-Gault) ≥ 50 ml/min or serum creatinine below 2 mg/dL
- •Females of childbearing potential (FCBP) must have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to initiating lenalidomide. The first pregnancy test must be performed within 10-14 days before and the second pregnancy test must be performed within 24 hours before lenalidomide is prescribed for Cycle 1 (prescriptions must be filled within 7 days).
- •FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting lenalidomide; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.
- •UCM IRB CRd vs. R Version 1.0 Page 11
- •Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
- •All study participants in the US must be consented to and registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of Revlimid REMS®.
- •Voluntary written informed consent
排除标准
- •Patients who have had more than 12 months of prior therapy. Patients outside of this window may be considered for inclusion on a case-by-case basis.
- •Patients who progressed after initial therapy.
- •Subjects whose therapy changed due to suboptimal response, intolerance, etc., remain eligible, provided they do not meet criteria for progression.
- •No more than two regimens for induction will be allowed excluding dexamethasone alone.
- •Evidence of progressive disease as per International Myeloma Working Group (IMWG) criteria
- •Patients who have already started or received post-transplant maintenance or consolidation regimen
- •Patients not able to tolerate lenalidomide or carfilzomib or dexamethasone
- •POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
- •Plasma cell leukemia
- •Waldenström's macroglobulinemia or IgM myeloma
- •Peripheral neuropathy ≥ Grade 2 at screening
- •Diarrhea > Grade 1 in the absence of antidiarrheals
- •CNS involvement
- •Pregnant or lactating females
- •Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.
- •Major surgery within 3 weeks prior to first dose
- •Myocardial infarction within 6 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- •Prior or concurrent deep vein thrombosis or pulmonary embolism
- •Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead ECG during screening
- •Uncontrolled hypertension or diabetes
- •Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
- •Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
- •Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone
- •Any clinically significant medical disease or condition that, in the Treating Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
研究组 & 干预措施
Lenalidomide (Control)
Active Comparator
Treatment with lenalidomide only
干预措施: Lenalidomide (Control) (Drug)
Experimental Combination Regimen
Experimental
Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
干预措施: Lenalidomide (Drug)
Experimental Combination Regimen
Experimental
Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
干预措施: Carfilzomib (Drug)
Experimental Combination Regimen
Experimental
Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Progression free survival rates in participants receiving drug combination
时间窗: 4 years
Measurement of time to disease worsening as measured by International Myeloma Working Group (IMWG) response criteria.
次要结局
- Treatment-related side effects(From date of screening until end of treatment)
- Rate of minimal residual negative disease (MRD) in participants receiving drug combination(3 years)
- Response rate in participants receiving drug combination(3 years)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
3 期
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple MyelomaDS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple MyelomaNCT00644228National Cancer Institute (NCI)525
进行中（未招募）
3 期
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple MyelomaDS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple MyelomaNCT00098475National Cancer Institute (NCI)452
进行中（未招募）
1 期
Research study to determine whether a combination of 3 drugs calledlenalidomide, carfilzomib and dexamethasone given to persons afterautologous stem cell (a young cell without a specific purpose from whichother cell types develop) transplant is better than lenalidomidemaintenance alone.MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2015-002380-42-PLPolish Myeloma Consortium180
进行中（未招募）
3 期
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaPlasma Cell MyelomaNCT01863550ECOG-ACRIN Cancer Research Group1,087
已完成
3 期
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.Relapsed Multiple MyelomaRefractory Multiple MyelomaNCT03158688Amgen466